Telaprevir: Hope on the Horizon, Getting Closer

Clinics in Liver Disease

Volumn 13, Issue 3, 2009, Pages 441-452

  Weisberg, Ilan S ^a   Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hepatitis C virus (HCV); NS3 4A; Protease inhibitor; STAT C; Telaprevir

Indexed keywords

ALPHA2A INTERFERON; BOCEPREVIR; CILUPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT INTERFERON; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOADING DRUG DOSE; PRURITUS; REVIEW; RNA TRANSLATION; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 67650700013     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.05.009     Document Type: Review

References (47)

1. Available at:. www.who.int/mediacentre/factsheets/fs164/en/index.html Accessed February 1, 2009
2. McHutchison J.G., Gordon S., Schiff E., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 (1998) 1485-1492
3. Fried M.W., Shiffman M., Reddy K., et al. PegInterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
4. Jacobson I.M., Brown Jr. R.S., Freilich B., et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46 (2007) 971-981
5. Sulkowski E., Lawitz M.L., Shiffman A.J., et al. Final results of the IDEAL (individualized dosing efficacy versus flatdosing to assess optimal pegylated interferon therapy) phase IIIB study. J Hepatol 48 (2008) S370-S371
6. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginteferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131 (2006) 470-477
7. Torriani F., Rodriguez-Torres M., Rockstroh J., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
8. Jacobson I.M., Brown Jr. R.S., McCone J., et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genoytpe 1. Hepatology 46 (2007) 982-990
9. Lindenbach B.D., and Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 436 (2005) 933-938
10. Bartenschlager R., Ahlborn-Lake L., Mous J., et al. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for the cleavage of the NS3/4 and NS4/5 junctions. J Virol 67 (1993) 3835-3844
11. Kolykhalov A.A., Mihalik K., Feinstone S.M., et al. Hepatitis C virus encoded enzymatic activities and conserved elements in the 3' nontranslated region are essential for virus replication in vivo. J Hepatol 74 (2000) 2046-2051
12. Foy E., Li K., Wang C., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300 (2003) 1145-1148
13. Li K., Foy E., Ferreon J.C., et al. Immune evasion by hepatitis C virus NS3/4A mediated protease cleavage of the toll like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102 (2005) 2992-2997
14. Lamarre D., Anderson P.C., Bailey M., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
15. Hinrichsen H., Benhamou Y., Wedemeyer, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis genotype 1 patients. Gastroenterology 127 (2004) 1347-1355
16. Perni R.B., Almquist S.J., Byrn R.A., et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50 (2006) 899-909
17. Lin K., Perni R.B., Kwong A.D., et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 50 (2006) 1813-1822
18. Reesink H.W., Zeuzem S., Weegink C.J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 131 (2006) 997-1002
19. Lin K., Kwong A.D., and Lin C. Combination of hepatitis C virus NS3-4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 48 (2004) 4784-4792
20. Lin C., Lin K., Luong Y.P., et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 279 (2004) 17508-17514
21. Forestier N., Reesink H.W., Weegink C.J., et al. Antiviral activity of Telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46 (2007) 640-648
22. Weegink C.J., Forestier N., Jansen P.L., et al. Final results of patients receiving Peg-Interferon-Alfa-2a (Ped-IFN) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir (VX-950) with Peg-IFN. [abstract]. Hepatology S46 (2007) 819A
23. Lawitz E., Rodriguez-Torres M., Muir A.J., et al. Antiviral effects and safety of Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 49 (2008) 163-169
24. Jacobson I.M., Everson G.T., Gordon S.C., et al. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with hepatitis C. Hepatology 46 (2007) 315A-316A
25. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360 (2009) 1827-1838
26. Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360 (2009) 1839-1850
27. Zeuzem S., Hezode C., Ferenci P., et al. Telaprevir in combination with peginterferon alfa-2a with or without ribavirin in the treatment of chronic hepatitis C. Final Results of the PROVE 2 study. Hepatology 48 S1 (2008) 418A-419A
28. McHutchison J.G., Shiffman M.L., Terrault N., et al. A Phase 2b study of telaprevir with peginterferon alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responder and relapsers following a prior course of peginterferon alfa2a/b and ribavirin therapy. PROVE 3 interim results. [abstract]. Hepatology 48 S1 (2008) 431A-432A
29. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126 (2004) 1015-1023
30. Poynard T., Schiff E., Terf R., et al. Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): Final results from the EPIC3 program. [abstract]. J Hepatol 48 (2008) S369
31. Shiffman M.L., Berg T., Poordad F., et al. A study of Telaprevir combined with peginterfeon-alfa-2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-alfa-2a and ribavirin treatment: Interim analysis. [abstract]. Hepatology 48 S1 (2008) 1135A-1136A
32. Lau D.T., Fish P.M., Sinha M., et al. Interferon regulatory factor-3 activation, hepatic interferon stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 47 (2008) 799-809
33. Forns X., Marecellin P., Goeser T., et al. Phase 2 study of Telaprevir administered Q8H or Q12H with peginterferon alfa-2a or alfa-2b and ribavirin in treatment naïve patients with genotype 1 hepatitis C: week 12 interim results. [abstract]. Hepatology 48 S1 (2008) 1136A-1137A
34. Neuman A.U., Lam N.P., Dahari H., et al. Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 282 (1998) 103-107
35. Lin C., Gates C.A., Rao B.G., et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 280 (2005) 36784-36791
36. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132 (2007) 1767-1777
37. Kieffer T.L., Sarrazin C., Miller J.S., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46 (2007) 631-639
38. Zhou Y., Muh U., Hanzelka B.L., et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg-155 variants. J Biol Chem 282 (2007) 22619-22628
39. Zhou Y., Bartels D.J., Hanzelka B.L., et al. Phenotypic characterization of resistant Val-36 variants in hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 52 (2008) 110-120
40. Colson P., Brouk N., Lembo, et al. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient. Hepatology 47 (2008) 766-767
41. Bartels D.J., Zhou Y., Zhang E., et al. Natural prevalence of HCV resistance variants with decreased sensitivity to NS3-4A protease inhibitors in treatment naïve subjects. J Infect Dis 198 (2008) 800-807
42. Kuntzen T., Timm J., Berical A., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48 (2008) 1769-1778
43. Muir A.J., Lawitz E.J., McHutchison J.G., et al. Viral responses in African-Americans, Latinos, and Caucasians in the US phase 2 study (PROVE1) of telaprevir with peginterferon alfa-2a and ribavirin in treatment naïve genotype 1 infected subjects with hepatitis C. [abstract]. Hepatology 48 S1 (2008) 1131A-1132A
44. Jacobson IM, Everson GT, Gordon SC, et al. Telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C, including African-Americans and those with bridging fibrosis: Subgroup analysis from the phase 2 PROVE 1 trial. 13th Abstract P-113. International Symposium on Viral Hepatitis and Liver Disease, Washington, DC, USA, March 20-24, 2009.
45. Shiffman M.L., Suter F., Bacon B.R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 (2007) 124-134
46. Foster G.R., Hezode C., Bronowicki J.P., et al. Activity of telaprevir alone or in combination with peginterferon alpha-2A and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: interim results of study C209. [abstract]. Hepatology 50 (2009) S22
47. Benhamou Y., Moussali J., Ratziu, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alpha-2A and ribavirin in treatment-naive genotype 4 HCV patients. [abstract]. Hepatology 50 (2009) S6